Over the last years, ADMA, the endogenous inhibitor of endothelial nitric oxide synthase (NOS3), has emerged as a cardiovascular molecule reflecting endothelial dysfunction and the vascular changes observed in essential HTN [40,41]. This evidence concerns the gene NOS3 and endothelial dysfunction.